Share on StockTwits

Research analysts at JPMorgan Chase & Co. initiated coverage on shares of ZS Pharma (NASDAQ:ZSPH) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating and a $43.00 price target on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 45.81% from the company’s current price.

Shares of ZS Pharma (NASDAQ:ZSPH) traded up 2.17% during mid-day trading on Monday, hitting $30.13. 252,116 shares of the company’s stock traded hands. ZS Pharma has a one year low of $26.10 and a one year high of $30.665. The stock has a 50-day moving average of $28.41 and a 200-day moving average of $28.41. The company’s market cap is $594.1 million.

Separately, analysts at BMO Capital Markets initiated coverage on shares of ZS Pharma in a research note on Monday. They set an “outperform” rating and a $38.00 price target on the stock.

ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.